back to US directory
us clinical guidance

Phenotype-led rosacea care

National Rosacea Society consensus for diagnosing rosacea by phenotype, selecting feature-specific treatment and recognizing ocular disease.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with cutaneous or ocular features consistent with rosacea. The National Rosacea Society update is expert consensus rather than a federal guideline. Acne, seborrheic dermatitis, lupus, periorificial dermatitis, contact dermatitis, medication flushing and other mimics must be reconsidered when the pattern is atypical.
sources for this section:NRS rosacea management update

The Bottom Line

  • Diagnose and treat the manifestations present rather than forcing every patient into an old subtype: persistent centrofacial erythema or phymatous change can be diagnostic, while combinations of major features can also establish the diagnosis.
  • Ask about flushing, papules and pustules, telangiectasia, edema, burning or stinging, skin dryness, eye irritation and tissue thickening, then agree which manifestations matter most to the patient.
  • Use gentle skin care, moisturizer, broad-spectrum sun protection and individualized trigger reduction for every phenotype; trigger advice should be based on the patient’s pattern, not a universal avoidance list.
  • Match therapy to the feature: topical or oral anti-inflammatory therapy for papules and pustules, vasoconstrictor or selected light or laser treatment for persistent erythema, and procedural treatment for established phymatous tissue when indicated.
  • Actively ask about ocular symptoms because lid-margin disease, dryness and irritation may coexist with modest skin findings; treatment can require coordinated ophthalmology care.
sources for this section:NRS rosacea management update

Practical clinical workflow

1
Document fixed erythema, flushing, inflammatory lesions, visible vessels, edema, phymatous change and eye symptoms, and check for comedones, scale, photosensitive distribution or medication timing that suggests a mimic.
2
Start a barrier-friendly routine and identify a small number of reproducible triggers using a diary; avoid irritating scrubs, toners and unstructured product changes that can obscure treatment response.
3
Choose one or more phenotype-directed interventions and explain that erythema, inflammatory lesions, telangiectasia and phymatous change respond to different modalities and on different time scales.
4
Review after an appropriate therapeutic interval, measure the target phenotype and adverse effects, and combine modalities when multiple features remain clinically important.
5
Assess eyelids and ocular symptoms at each review and refer promptly for pain, photophobia, visual change, corneal concern or persistent symptoms despite basic lid and surface care.
sources for this section:NRS rosacea management update

Safety boundaries and escalation

  • Eye pain, photophobia, reduced vision, marked unilateral redness or suspected keratitis requires urgent ophthalmic assessment rather than routine rosacea follow-up.
  • A rapidly enlarging phymatous lesion, marked asymmetry, ulceration or bleeding needs evaluation for malignancy or another diagnosis before cosmetic treatment.
  • Avoid assuming every red face is rosacea; systemic symptoms, photosensitivity, muscle weakness, medication exposure or an unusual distribution should trigger a broader diagnostic work-up.
  • Oral tetracyclines, vasoconstrictors, isotretinoin and device procedures each have distinct pregnancy, cardiovascular, ocular or procedural risks and require their specific labeling and expertise.
sources for this section:NRS rosacea management update

Localization

The National Rosacea Society publication is a phenotype-based expert consensus reviewed by an international panel, not a US government recommendation. FDA labeling, local laser expertise and insurance coverage determine available care.
sources for this section:NRS rosacea management update

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. National Rosacea Society Expert CommitteeStandard management options for rosacea: the 2019 update by the National Rosacea Society Expert CommitteeDOI 10.1016/j.jaad.2020.01.077 · Expert consensus and review panel publication in JAAD 2020;82(6):1501–1510 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.